Sugi Predict

Sugi Predict / Compounds / SCHEMBL3199744

SCHEMBL3199744

SCHEMBL3199744

Cc1ccc(NC(=O)Nc2cc(CN3CCN(C(=O)O)CC3)ccc2C(F)(F)F)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 7/20 0.45
▸ PHGDH O43175 2/20 0.43
▸ NPC1 O15118 3/20 0.41
▸ TP53 P04637 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ RET P07949 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ FGFR4 P22455 3/20 0.41
▸ P2RY1 P47900 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399196 0.92 NPC1 (0.43) FAAHPHGDHNPC1TP53RAB9A
SCHEMBL3204614 0.89 FAAH (0.45) FAAHNPC1TP53RAB9APOLB
SCHEMBL3196669 0.89 FAAH (0.47) FAAHNPC1TP53RAB9APOLB
SCHEMBL3197411 0.87 SMN1; SMN2 (0.50) FAAHNPC1TP53RAB9APOLB
SCHEMBL3196744 0.84 FAAH (0.40) FAAHNPC1TP53RAB9APOLB
SCHEMBL3205546 0.84 KDR (0.51) FAAHKDR
SCHEMBL3198046 0.82 ACKR3 (0.52) FAAHNPC1TP53RAB9APOLB
SCHEMBL402276 0.82 MEN1 (0.46) FAAHNPC1TP53RAB9APOLB
SCHEMBL3209186 0.81 FAAH (0.44) FAAHPHGDHNPC1TP53RAB9A
SCHEMBL7859143 0.80 FAAH (0.44) FAAHNPC1TP53RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10322102-B2 Benzo lipoxin analogues UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2019-06-18 — — US claimed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-10322102-B2 Benzo lipoxin analogues UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2019-06-18 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060270734-A1 Benzo lipoxin analogues UNIVERSITY OF SOUTHERN CALIFORNIA 2006-11-30 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed
US-20050203184-A1 Benzo lipoxin analogues PETASIS NICOS A (US) 2005-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 FAAH 4811/4885PHGDH 1644/4885NPC1 4691/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 FAAH 4661/4885PHGDH 3194/4885NPC1 4804/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20050203184-A1 Benzo lipoxin analogues ALOX15B, ALOX12, ALOX15 FAAH 176/4885PHGDH 2041/4885NPC1 2233/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 FAAH 4811/4885PHGDH 1644/4885NPC1 4691/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 FAAH 3155/4885PHGDH 1965/4885NPC1 4826/4885
US-10322102-B2 Benzo lipoxin analogues ALOX15B, ALOX12, ALOX15 FAAH 176/4885PHGDH 2041/4885NPC1 2233/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 FAAH 4697/4885PHGDH 2118/4885NPC1 4608/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 FAAH 3155/4885PHGDH 1965/4885NPC1 4826/4885
US-20060270734-A1 Benzo lipoxin analogues ALOX15B, ALOX12, ALOX15 FAAH 176/4885PHGDH 2041/4885NPC1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.